You are here: Industry Insights > lymphoma

News List

NICE asks BMS for more data before approving cancer drug europeanpharmaceuticalreview
May 08, 2019
NICE has asked Bristol Myers Squibb, who manufacture nivolumab (Opdivo), to provide more information on its effectiveness for treating Hodgkin lymphoma…
Redesigned CAR-T eliminates dangerous cytokine release syndrome in lymphoma trial fiercebiotech
April 23, 2019
Personalized CAR-T treatments for leukemia and lymphoma have offered new hope for patients with tough-to-treat disease, but the engineered cell therapies can cause a dangerous immune reaction called cytokine release syndrome (CRS).
Cell therapy rejected for aggressive adult lymphoma on the NHS europeanpharmaceuticalreview
April 18, 2019
A CAR-T immunotherapy for adults with an aggressive form of non-Hodgkin lymphoma has been provisionally rejected by the NHS…
Celgene gets fast FDA review of Revlimid combo in lymphoma pharmaphorum
February 28, 2019
Celgene is closing in on yet another new indication for its blood cancer blockbuster Revlimid, with the FDA starting a priority review of the drug in combination with Roche’s Rituxan.
Roche’s patent cliff just got steeper as FDA approves Celltrion’s Rituxan biosimilar Truxima fiercepharma
December 05, 2018
Roche’s trio of cancer blockbusters—Rituxan, Avastin and Herceptin—brought in $20 billion in sales last year, with one-fifth of that haul coming from lymphoma treatment Rituxan.
FDA Approves First-Line Treatment for Peripheral T-Cell Lymphoma americanpharmaceuticalreview
November 20, 2018
The U.S. Food and Drug Administration (FDA) expanded the approved use of Adcetris (brentuximab vedotin) injection in com
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma fiercepharma
November 05, 2018
Celgene’s Revlimid may have slipped in tandem with Roche’s Rituxan in previously untreated follicular lymphoma patients. But in the second-line setting, the drug has a win.
Curis moves up COO as CEO Fattaey leaves company fiercebiotech
September 27, 2018
James Dentzer has been leading the company’s pre-commercial planning for fimepinostat, which received an FDA fast-track designation in relapsed or refractory diffuse large B-cell lymphoma in May.
NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma pharmatimes
September 20, 2018
The National Institute for Health and Care Excellence has turned down NHS funding for use of Novartis’ CAR-T therapy Kymriah in adults...
NICE says no to Kymriah for adult lymphoma despite offer on price biopharmadive
September 20, 2018
Novartis slashed the U.K. list price for Kymriah by nearly a quarter compared to the U.S. for treating ALL patients under 25 whose disease was refractory, in relapse post-transplant or in second or later relapse.

Previous page 1 2 3 4 5 Next page